NCT02268552View on ClinicalTrials.gov

An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 2, 2015

Primary Completion Date

December 29, 2022

Study Completion Date

December 29, 2022

Conditions
Spinal Muscular Atrophy
Interventions
DRUG

branaplam

Trial Locations (14)

1606

Novartis Investigative Site, Sofia

3000

Novartis Investigative Site, Leuven

9000

Novartis Investigative Site, Ghent

20133

Novartis Investigative Site, Milan

45147

Novartis Investigative Site, Essen

119049

Novartis Investigative Site, Moscow

127412

Novartis Investigative Site, Moscow

197341

Novartis Investigative Site, Saint Petersburg

400120

Novartis Investigative Site, Volgograd

620134

Novartis Investigative Site, Yekaterinburg

2100 O

Novartis Investigative Site, Copenhagen

00165

Novartis Investigative Site, Roma

04 730

Novartis Investigative Site, Warsaw

50 420

Novartis Investigative Site, Wroclaw

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY